Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study (VEGF PP)

Causal Association Between Plasma Vascular Endothelial Growth Factor Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study

This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.

Study Overview

• Status: Not yet recruiting
• Conditions: Placenta Previa

Detailed Description

Placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. This study utilizes Mendelian randomization (MR) to explore the potential causal link between plasma levels of VEGF family proteins (including VEGFA, VEGFB, VEGFC, VEGFD, and PLGF) and the risk of placenta previa. By using genome-wide association study (GWAS) data from the UK Biobank and FinnGen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. The MR analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between VEGF proteins and placenta previa.

• Study Type: Observational
• Enrollment (Estimated): 207473

Contacts and Locations

• Study Contact: Name: Zhibin Xu; Phone Number: +8615816832640; Email: unignorable_xuzhibin@outlook.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

This study analyzes data from European populations included in genome-wide association studies (GWAS) from UK Biobank and FinnGen, focusing on individuals with available plasma VEGF family protein levels and placenta previa data.

Description

Inclusion Criteria:

• Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.

Exclusion Criteria:

• Participants with incomplete or missing data on plasma VEGF levels or placenta previa.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Causal relationship between plasma VEGFA levels and the risk of placenta previa	This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.	Data analysis and outcome assessment will be completed by December 2024

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Causal relationship between plasma VEGFB levels and the risk of placenta previa	This outcome measures the association between plasma VEGFB levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.	Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma VEGFC levels and the risk of placenta previa	This outcome measures the association between plasma VEGFC levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.	Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma PLGF levels and the risk of placenta previa	This outcome measures the association between plasma PLGF levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.	Data analysis and outcome assessment will be completed by December 2024

Collaborators and Investigators

• Sponsor: Guangzhou Institute of Respiratory Disease
• Collaborators: First People's Hospital of Foshan; The Second People's Hospital of Foshan; Maternal and Child Health Hospital of Foshan

Study record dates

Study Major Dates

• Study Start (Estimated): September 25, 2024
• Primary Completion (Estimated): November 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: September 24, 2024
• First Submitted That Met QC Criteria: September 26, 2024
• First Posted (Actual): October 1, 2024

Study Record Updates

• Last Update Posted (Actual): October 1, 2024
• Last Update Submitted That Met QC Criteria: September 26, 2024
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: Angiogenesis; Pregnancy Complications; Vascular Endothelial Growth Factor (VEGF); Mendelian Randomization; Placental Development
• Additional Relevant MeSH Terms: Pregnancy Complications; Obstetric Labor Complications; Placenta Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Placenta Previa
• Other Study ID Numbers: FSKY20240924

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No